Hepatitis C News and Research RSS Feed - Hepatitis C News and Research

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

The hepatitis C virus is usually transmitted through contact with the blood of an infected individual and, most commonly, people catch it through sharing contaminated needles when injecting illegal drugs.

Hepatitis C infection is categorized into an acute and a chronic stage. The acute phase describes the first 6 months of infection when there are not necessarily any symptoms. Around one quarter of people manage to clear the infection during this stage before disease progresses to the chronic stage.

People who go on to develop chronic hepatitis C may develop jaundice which turns the skin and whites of the eyes yellow. This is caused by the build-up of a yellow-colored substance in the blood called bilirubin that would usually be broken down by the liver if it was healthy. Chronic infection may eventually cause fibrosis and scarring (cirrhosis) of the liver, liver cancer or end stage liver failure.

Hepatitis C can be treated with antiviral medications that that are designed to disrupt the multiplication of virus particles inside the body and prevent liver damage.
New analysis looks at costly impact of new Hepatitis C treatments in California

New analysis looks at costly impact of new Hepatitis C treatments in California

A new analysis and infographic released today estimate California's exposure to high-priced Hepatitis C medications could range from hundreds of millions of dollars, even if only 5 percent of Californians infected with Hepatitis C receive treatment through state programs. [More]
Exhausted army of immune cells may damage the very body they are supposed to protect

Exhausted army of immune cells may damage the very body they are supposed to protect

An 'exhausted' army of immune cells may not be able to fight off infection, but if its soldiers fight too hard they risk damaging the very body they are meant to be protecting, suggests new research from the University of Cambridge. [More]
Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

A rapid, sensitive, and accurate method to detect drug resistant hepatitis C virus (HCV) mutants has been developed. Researchers at Hiroshima University established a system to rapidly and accurately measure the presence of HCV Y93H drug resistant mutant strains, and evaluate the proportion of patients harboring this mutation prior to treatment. [More]
AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The American Association for the Study of Liver Diseases, in partnership with the Infectious Diseases Society of America and in collaboration with the International Antiviral Society-USA, created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV). [More]
Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Congress needs to immediately lift the ban on federal funding for needle exchange programs to counter the threat of HIV outbreaks among injection drug users like the one that has seen an alarming number of new cases erupt in a single rural Indiana county. [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
Scientists reveal new combination method that efficiently destroys cancer cells

Scientists reveal new combination method that efficiently destroys cancer cells

Scientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells. [More]
Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter Diagnostics supports IFCC-EFLM EuroMedLab 2015 with a showcase of solutions to improve workflow for the diagnostics laboratory. Held from 22-24 June 2015 at the Paris Palais des Congrès France, the company demonstrates its dedication to moving the clinical diagnostic lab forward with its total laboratory solution—from automation, chemistry, immunoassay and haematology to microbiology and its new molecular diagnostics system. [More]
AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited. [More]
Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"). [More]
Penn Medicine researchers explore primary player involved in T cell exhaustion

Penn Medicine researchers explore primary player involved in T cell exhaustion

Sometimes even cells get tired. When the T cells of your immune system are forced to deal over time with cancer or a chronic infection such as HIV or hepatitis C, they can develop 'T cell exhaustion,' becoming less effective and losing their ability to attack and destroy the invaders of the body. [More]
Research findings could help guide development of potential treatments for HCV

Research findings could help guide development of potential treatments for HCV

Warring armies use a variety of tactics as they struggle to gain the upper hand. Among their tricks is to attack with a decoy force that occupies the defenders while an unseen force launches a separate attack that the defenders fail to notice. [More]
AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan. [More]
New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA. [More]
Risk prediction model can help target hepatitis C treatment to patients with most urgent need

Risk prediction model can help target hepatitis C treatment to patients with most urgent need

A team of researchers at the University of Michigan Health System has developed a risk prediction model that helps identify which hepatitis C patients have the most urgent need for new anti-viral drugs. [More]
Changes in cell membrane play pivotal role in how HCV replicates

Changes in cell membrane play pivotal role in how HCV replicates

New research from the University of Southampton has identified how changes in the cell membrane play a pivotal role in how the Hepatitis C virus replicates. [More]
CLDF collaborates with Walgreens to offer free rapid HCV testing

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country. [More]

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths. [More]
Investing in new hepatitis C therapies may have significant economic impact

Investing in new hepatitis C therapies may have significant economic impact

While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the U.S. and five European countries, according to a new study (abstract 228) released today at Digestive Disease Week® (DDW) 2015. [More]
MD Anderson researchers find significant clinical variations among liver cancer patients

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
Advertisement